AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04069780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection (4mg/0.1ml)
Description: Injection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Intravitreal injection (4mg/0.1ml) of triamicinolone acetonide will be done using a 30-31 gauge needle at a distance of 3.5 mm from the limbus in aphakic or pseudophakic patients, and 4 mm in phakic patients. The needle will be then removed with application of cotton tipped applicator over the entry site.~-IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.
Study NCT04069780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superachoroidal injection (4 mg/0.1ml)
Description: Injection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Suprachoroidal injection (4mg/0.1ml) of triamcinolone acetonide will be done using a custom-made 30-31 gauge needle with a sleeve to prevent further penetration of the needle into the vitreous cavity. Injection will be done at approximately 4 mm from the limbus.~* IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.~* UBM assessment will be done 24 hours following injection to confirm targeting of the suprachoroidal space.
Study NCT04069780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprachoroidal injection (2mg/0.1ml)
Description: njection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Suprachoroidal injection (2mg/0.1ml) of triamcinolone acetonide will be done using a custom-made 30-31 gauge needle with a sleeve to prevent further penetration of the needle into the vitreous cavity. Injection will be done at approximately 4 mm from the limbus.~* IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.~* UBM assessment will be done 24 hours following injection to confirm targeting of the suprachoroidal space.
Study NCT03279835 — intervention group
Intervention type: OTHER
Intervention: Classic evaluation of neurocognitive functions
Description: Symbol Digit Modalities Test (SDMT)
Study NCT03279835 — intervention group
Intervention type: OTHER
Intervention: New evaluation of neurocognitive functions
Description: Cognitive Speed Computerized Test (CSCT)
Study NCT04886479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No lens
Study NCT04346433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restricted Sleep
Description: During the restricted sleep condition adolescents will sleep 4 hours ±1 hour (0100-0500). This condition will last 1 night.
Study NCT04886479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: Low Dk HEMA contact lens worn for 3 hours
Study NCT02028026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: 10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
Study NCT02028026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: 20 mg/day for 2 weeks and then 40 mg/day for 6 weeks
Study NCT02753309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Study NCT02831257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Study NCT01780935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injections of 0.5 mg Ranibizumab
Study NCT03360630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 plus DC-CIK
Description: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal. DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
Study NCT03360630 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-PD-1 alone
Description: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
Study NCT03502616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tofacitinib
Description: Oral administration twice per day
Study NCT03502616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Oral administration twice per day
Study NCT04038528 — intervention group
Intervention type: BEHAVIORAL
Intervention: telemonitoring of T2DM
Description: Baseline record of:~* Weight~* Height~* BMI~* Abdominal circumference~* Winsor Index~* ECG~* Retinography~* Blood level of (fasting values): total cholesterol, HDL cholesterol, LDL cholesterol, blood sugar, triglycerides, glycated hemoglobin These parameters will be checked again at 3, 6 and 18 months in the two groups.~Telemedicine group (intervention):~* Blood sugar (two measurements per week).~* Body weight (weekly)~* Blood pressure (weekly) Use of devices that allow the automatic upload of data via wi-fi or web is allowed~Control group (control):~Routine appointments scheduled by their GPs and specialists in outpatient clinics to record blood sugar levels as per standard GP or specialist physician's indications.~Blood sugar level is measured in mg/dl in a drop of capillary blood with the use of standard glucose meter
Study NCT01033214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular repair of TAA in the descending Thoracic Aorta
Description: Usage of the TAArget thoracic stent graft for treatment of TAA in the Descending Thoracic Aorta.
Study NCT01373632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Firebird 2 sirolimus-eluting stent
Description: the Firebird 2 sirolimus-eluting stent is a SES with durable polymer based on Co-Cr stent platform
Study NCT01373632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excel sirolimus-eluting stent
Description: the Excel sirolimus-eluting stent is a stent with biodegradable polymer (PLA) based on stainless steel (316L) stent platform
Study NCT01570530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac surgery
Description: Atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
Study NCT01570530 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiac surgery
Description: Without atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
Study NCT03281122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT03281122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT03281122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986224
Description: Specified dose on specified days
Study NCT03281122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986224
Description: Specified dose on specified days
Study NCT02847299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: increase of cough peak flow (Astral ventilator)
Description: instrumental increase of cough peak flow with a ventilator by hyper-insufflation and with air stacking method
Study NCT01566175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neovac coronary sinus reducer
Description: reducer
Study NCT01898702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes expert patients programme
Description: Nine-weekly informative and educational sessions by a teaching patient who has experience on diabetes
Study NCT01440686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: A single dose 5.0mg administered subcutaneously(under the skin) via Genotropin
Study NCT01440686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, oral administrations
Study NCT01498432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heliox21
Description: For Heliox21 the percentage of O2 will match the percentage of O2 prior to extubation, and Helium will make up the remainder (e.g. Helium 65% + O2 35%), and the O2 concentration will be titrated as their clinical condition indicates (as O2 increases Helium will decrease and vice versa).
Study NCT01498432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Air O2
Description: For Air-O2 the percentage of O2 delivered will match the patient's percentage of O2 prior to extubation, and will be titrated as their clinical condition indicates.
Study NCT02561169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
Study NCT02561169 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Those randomized to the control arm will receive 75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
Study NCT03786952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress immediately before learning in males
Description: Male participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
Study NCT03786952 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham control immediately before learning in males
Description: Male participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
Study NCT03786952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress 30 minutes before learning in males
Description: Male participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
Study NCT03786952 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham control 30 minutes before learning in males
Description: Male participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
Study NCT03786952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress immediately before learning in females
Description: Female participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
Study NCT03786952 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham control immediately before learning in females
Description: Female participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
Study NCT03786952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress 30 minutes before learning in females
Description: Female participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
Study NCT03786952 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham control 30 minutes before learning in females
Description: Female participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
Study NCT04346433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adequate Sleep
Description: During the adequate sleep condition adolescents will sleep 9 hours ±1 hour (2100- 0800). This condition will last 1 night.
Study NCT04446455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: InVEST: Increased Velocity Exercise Specific to Task
Description: Functional Power Training
Study NCT02219191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin tablet 20 mg
Description: Approval No.: H19990258
Study NCT04446455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: InVEST: Increased Velocity Exercise Specific to Task
Description: Functional Power Training
Study NCT04446455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAPAT: Tonic and Phasic Alertness Training
Description: Computerized cognitive training.
Study NCT03842007 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Barostat Study
Description: Contractions will be recorded with a balloon inserted into the rectum and inflated
Study NCT03842007 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fecoflowmetry
Description: Rectum will be filled with a small amount of paste.Two thin catheters will be inserted into the anus to measure pressures and electrical activity (electromyography or EMG). Subjects will be asked to sit on a commode, contract (squeeze) your anal muscles, blow into a balloon, and expel the paste into the commode.
Study NCT02424630 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound-guided ISB
Description: ISB was performed by one anesthesiologist under ultrasound-guidance. The superior, middle, and inferior trunks of the brachial plexus were identified approximately 2 cm above the clavicle. A 50 mm 22-gauge needle was introduced percutaneously using an out-of-plane technique. The needle was placed beside each trunk in succession, and 2.5 mL ropivacaine was injected into each site. The total volume of ropivacaine used for ISB was 7.5 mL.
Study NCT02424630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ISB
Description: ISB was performed by one anesthesiologist under ultrasound-guidance. The superior, middle, and inferior trunks of the brachial plexus were identified approximately 2 cm above the clavicle. A 50 mm 22-gauge needle was introduced percutaneously using an out-of-plane technique. The needle was placed beside each trunk in succession, and 2.5 mL ropivacaine was injected into each site. The total volume of ropivacaine used for ISB was 7.5 mL.
Study NCT02424630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroscopy-guided SSNB
Description: At the end of the surgery, SSNB was performed under arthroscopic guidance by one shoulder arthroscopist. The suprascapular ligament was found using the lateral portal for visualization. The supraclavicular ligament was visualized at the end of the conoid ligament when the arthroscope was advanced following the coracoclavicular ligament. A 23-gauge spinal needle was introduced in a posteroanterior direction at a 20° angle percutaneously and 7 cm medial to the lateral margin of the acromion. Then, the needle was placed at the upper margin of the suprascapular ligament and advanced slightly under arthroscopy-guidance. After suctioning the saline from the portal, the injection material was administered according to the random assignment.
Study NCT02424630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All the regional blocks in this study were performed using ropivacaine, except for arthroscopy-guided SSNB using placebo (10 mL normal saline)
Study NCT02424630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All the regional blocks in this study were performed using ropivacaine, except for arthroscopy-guided SSNB using placebo (10 mL normal saline)
Study NCT02424630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: All the regional blocks in this study were performed using 10mL ropivacaine.
Study NCT00184132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychiatric intensive care unit in Norwegian home style
Study NCT00184132 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric intensive care unit sparsely furnished and not decorated
Study NCT01265576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Participants will be on sorafenib at least 30 days before randomization into either the Treatment or Control Arms. Sorafenib will be administered according to the package insert unless contraindicated based on physician expertise.
Study NCT01265576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sorafenib
Description: Participants will be on sorafenib at least 30 days before randomization into either the Treatment or Control Arms. Sorafenib will be administered according to the package insert unless contraindicated based on physician expertise.
Study NCT01265576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-122 (propranolol plus etodolac)
Description: Participants randomized to the VT-122 regimen (sorafenib plus VT-122) will receive oral doses of propranolol and etodolac, which will be titrated over a period of 3 weeks until the participant reaches a maximum tolerated dose (MTD)\[no higher than 60 mg propranolol, twice daily (BID)/300 mg etodolac, BID\]. Once the individual MTD has been reached, participants will enter a Maintenance Treatment period, and will receive the VT-122 regimen (propranolol and etodolac, co administered orally) on a continuous BID dosing schedule for a maximum of twelve 4-week cycles.
Study NCT03322514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin-Propionate Esters
Description: Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.
Study NCT01265576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the Control Arm (sorafenib with placebo) will receive placebo for the same periods as participants randomized to the Treatment Arm. Participants in the Control Arm will undergo the same visits and mock dose escalation.
Study NCT04052867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine
Description: Slow bolus of lignocaine is given over 15 min before the start of surgery, followed by infusion of lignocaine
Study NCT04052867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: An equivalent volume of normal saline is given
Study NCT01512381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of CRT device
Description: RV lead of CRT system is implanted into the middle part of interventricular septum
Study NCT01512381 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of conventional VVI(R) pacemaker
Description: RV lead is implanted into the middle part of interventricular septum
Study NCT02335970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training group
Description: After 1 week~* Chest expansions~* Static thoracic extension in prone~* Lateral flexion of the spine in standing~* Bilateral shoulder flexion~* Shoulder external rotation of shoulders~* Rotation of the thoracic spine in sitting~* Static back extensor strength in prone~After 1 month~* Thoracic extension, rotation and flexion abduction~* Hand in neck and in back~* Bilateral active flexion abduction~* Strength training of leg muscles~* Static back extensor strength~After 2 months~* Strength training of legs and back muscles~* Push-ups against a wall~* Thoracic extension in sitting and standing~* Thoracic rotation in lying~* Stretching of mm. pectoralis Training was performed daily with 10 rep of each exercise
Study NCT00900159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)